Stem Cell Research & Therapy · 2023 · 56 citations · 25 references
MedicineCardiologyTranslational SciencesCell TherapyRegenerative MedicineStem Cell TransplantationAcute Coronary SyndromesHeart TransplantationIschemic Heart DiseaseMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyBone Marrow-derived Mesenchymal Stromal CellsBooster Dose EfficacyCardiac Cell TherapyLeft Ventricular Ejection Fraction DeclineMesenchymal Stromal Cell Allogeneic TherapyMesenchymal Stromal Cell Clinical TrialsTransplantationVentricular Ejection Fraction Assessment
BACKGROUND: Mesenchymal stromal cell (MSC) transplantation can improve the left ventricular ejection fraction (LVEF) after an acute myocardial infarction (AMI). Transplanted MSCs exert a paracrine effect, which might be augmented if repeated doses are administered. This study aimed to compare the effects of single versus double transplantation of Wharton's jelly MSCs (WJ-MSCs) on LVEF post-AMI. METHODS: We conducted a single-blind, randomized, multicenter trial. After 3-7 days of an AMI treated successfully by primary PCI, 70 patients younger than 65 with LVEF < 40% on baseline echocardiography were randomized to receive conventional care, a single intracoronary infusion of WJ-MSCs, or a repeated infusion 10 days later. The primary endpoint was the 6-month LVEF improvement as per cardiac magnetic resonance (CMR) imaging. RESULTS: The mean baseline EF measured by CMR was similar (~ 40%) in all three groups. By the end of the trial, while all patients experienced a rise in EF, the most significant change was seen in the repeated intervention group. Compared to the control group (n = 25), single MSC transplantation (n = 20) improved the EF by 4.54 ± 2%, and repeated intervention (n = 20) did so by 7.45 ± 2% when measured by CMR imaging (P < 0.001); when evaluated by echocardiography, these values were 6.71 ± 2.4 and 10.71 ± 2.5%, respectively (P < 0.001). CONCLUSIONS: Intracoronary transplantation of WJ-MSCs 3-7 days after AMI in selected patients significantly improves LVEF, with the infusion of a booster dose 10 days later augmenting this effect. TRIAL REGISTRATION: Trial registration: Iranian Registry of Clinical Trials, IRCT20201116049408N1. Retrospectively Registered 20 Nov. 2020, https://en.irct.ir/trial/52357.
25
Heart Disease and Stroke Statistics—2012 Update
Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2011 · 7.2K citations · Full text
Bone marrow cells regenerate infarcted myocardium
Donald Orlic, Jan Kajstura, Stefano Chimenti et al. · Nature · 2001 · 5.2K citations
Joshua M. Hare, Joel E. Fishman, Gary Gerstenblith et al. · JAMA · 2012 · 1.2K citations · Full text